CA3025734A1 — Oral composition of celecoxib for treatment of pain
Assigned to Scilex Holding Co · Expires 2017-12-07 · 8y expired
What this patent protects
The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted- State Simulated Gastri…
USPTO Abstract
The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted- State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37°C ± 0.5°C and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.
Drugs covered by this patent
- Celebrex (celecoxib) · Pfizer Inc. (originally Searle/Pharmacia)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.